

Dear Editors and Reviewers:

Thank you for your comments concerning our manuscript entitled "Pomolidomide for a patient with amyloid light amyloidosis who was relapsed/refractory to both bortezomib and daratumumab: A case report" (Manuscript NO.: 79022, Case Report). Those comments are all valuable and very helpful for revising and improving our paper. We have studied comments carefully and have made correction and which we hope meet with approval.

Once again, thank you very much for your comments and suggestions.

Yours sincerely,

Xian Li

12 Oct. 2022